

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | | |
|-------------------------------------|--|
| n/a | Confirmed |
| ☐ | ☒ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| ☐ | ☒ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| ☐ | ☒ The statistical test(s) used AND whether they are one- or two-sided
<i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i> |
| ☐ | ☒ A description of all covariates tested |
| ☐ | ☒ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| ☐ | ☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| ☒ | ☐ For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
<i>Give P values as exact values whenever suitable.</i> |
| ☒ | ☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| ☒ | ☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| ☒ | ☐ Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection: Nikon C2-NIS elements, Image Lab,

Data analysis: Graphad prism 7, Image J, Image Lab, Bioconductor Software

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

All data supporting the findings of this study are available from the corresponding author upon request. All organized data by figure panel will be available through a direct link to a server.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- ☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	No sample size was pre-calculated.
Data exclusions	As stated in the text, datapoints that were 2 standard deviation from mean were considered as putative outlayer and an outlayer t-test was applied (Graphad) to define if the datapoint was or not an outlayer.
Replication	All attempts were succesfull. Diferent labs in different institutions and countriies were able to reporoduce relevant findings, including: RT-qPCR (mRNA Decay), Comet Assay, WB, flow-cytometry, drosophila experiments, etc.
Randomization	Drosophila and mice experiments were randomized .
Blinding	Blinded studies were carried on comet assay, and animals experiment.

Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	<i>Briefly describe the study type including whether data are quantitative, qualitative, or mixed-methods (e.g. qualitative cross-sectional, quantitative experimental, mixed-methods case study).</i>
Research sample	<i>State the research sample (e.g. Harvard university undergraduates, villagers in rural India) and provide relevant demographic information (e.g. age, sex) and indicate whether the sample is representative. Provide a rationale for the study sample chosen. For studies involving existing datasets, please describe the dataset and source.</i>
Sampling strategy	<i>Describe the sampling procedure (e.g. random, snowball, stratified, convenience). Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient. For qualitative data, please indicate whether data saturation was considered, and what criteria were used to decide that no further sampling was needed.</i>
Data collection	<i>Provide details about the data collection procedure, including the instruments or devices used to record the data (e.g. pen and paper, computer, eye tracker, video or audio equipment) whether anyone was present besides the participant(s) and the researcher, and whether the researcher was blind to experimental condition and/or the study hypothesis during data collection.</i>
Timing	<i>Indicate the start and stop dates of data collection. If there is a gap between collection periods, state the dates for each sample cohort.</i>
Data exclusions	<i>If no data were excluded from the analyses, state so OR if data were excluded, provide the exact number of exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.</i>
Non-participation	<i>State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no participants dropped out/declined participation.</i>
Randomization	<i>If participants were not allocated into experimental groups, state so OR describe how participants were allocated to groups, and if allocation was not random, describe how covariates were controlled.</i>

Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	<i>Briefly describe the study. For quantitative data include treatment factors and interactions, design structure (e.g. factorial, nested, hierarchical), nature and number of experimental units and replicates.</i>
Research sample	<i>Describe the research sample (e.g. a group of tagged Passer domesticus, all Stenocereus thurberi within Organ Pipe Cactus National Monument), and provide a rationale for the sample choice. When relevant, describe the organism taxa, source, sex, age range and any manipulations. State what population the sample is meant to represent when applicable. For studies involving existing datasets, describe the data and its source.</i>
Sampling strategy	<i>Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.</i>
Data collection	<i>Describe the data collection procedure, including who recorded the data and how.</i>
Timing and spatial scale	<i>Indicate the start and stop dates of data collection, noting the frequency and periodicity of sampling and providing a rationale for</i>

Timing and spatial scale	<i>these choices. If there is a gap between collection periods, state the dates for each sample cohort. Specify the spatial scale from which the data are taken</i>
Data exclusions	<i>If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.</i>
Reproducibility	<i>Describe the measures taken to verify the reproducibility of experimental findings. For each experiment, note whether any attempts to repeat the experiment failed OR state that all attempts to repeat the experiment were successful.</i>
Randomization	<i>Describe how samples/organisms/participants were allocated into groups. If allocation was not random, describe how covariates were controlled. If this is not relevant to your study, explain why.</i>
Blinding	<i>Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.</i>
Did the study involve field work?	☐ Yes ☐ No

Field work, collection and transport

Field conditions	<i>Describe the study conditions for field work, providing relevant parameters (e.g. temperature, rainfall).</i>
Location	<i>State the location of the sampling or experiment, providing relevant parameters (e.g. latitude and longitude, elevation, water depth).</i>
Access and import/export	<i>Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing authority, the date of issue, and any identifying information).</i>
Disturbance	<i>Describe any disturbance caused by the study and how it was minimized.</i>

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

Methods

n/a	Involved in the study
☐	☒ Antibodies
☐	☒ Eukaryotic cell lines
☒	☐ Palaeontology
☐	☒ Animals and other organisms
☒	☐ Human research participants
☒	☐ Clinical data

n/a	Involved in the study
☒	☐ ChIP-seq
☐	☒ Flow cytometry
☒	☐ MRI-based neuroimaging

Antibodies

Antibodies used	The following antibodies diluted in blocking solution were used in this study: anti-BiP 1:1000 (Abcam, Cat. ab21685); Anti-phosphorylated S139-H2AX 1:5000 (Millipore, Cat. 05-636), anti-DDIT3 (CHOP) 1:1000 (Santa Cruz, Cat. sc-575), anti-XBP1s 1:1000 (Santa Cruz, Cat. 7160), anti-ATF4 1:2000 (Santa Cruz, Cat. sc-200), anti-HSP90 1:5000 (Santa Cruz, Cat. sc-13119), anti-IRE1α (14C10) (Santa Cruz, Cat. 3294), anti-Chk1 1:1000 (Santa Cruz, Cat. sc-8408), anti-Chk2 1:1000 (Santa Cruz, Cat. sc-17747), anti-phosphorylated-Chk2, Thr68 1:1000 (Santa Cruz, Cat. sc-16297-R), anti-ATM 1:1000 (Santa Cruz, Cat. sc-7129), anti-HA 1:1000 (Roche, Cat. 11666606001), anti-PP2A A 1:1000 (Cell Signaling technology, Cat. 2041S), anti-RuvbL1 1:1000 (Cell Signaling technology, Cat. 12300), anti-eIF2α 1:000 (Cell Signaling technology, Cat. 9722), anti-phosphorylated-eIF2α 1:1000 (Cell Signaling technology, Cat. 9721), anti-PERK 1:1000 (Cell Signaling technology, Cat. 3192), anti-IRE1α 1:1000 (Cell Signaling technology, Cat. 3294), anti-phosphorylated-Chk1, Ser348 1:1000 (Cell Signaling, Cat. 2341), anti-HA 1:1000 (Cell Signalling, Cat. 3724), anti-GAPDH 1:1000 (Cell Signaling, Cat. 21185), anti-Abl 1:1000 (Sigma, Cat. A5844), anti-phosphorylated-c-Abl, pTyr412, 1:1000 (Sigma, Cat. C52490), anti-SMC1 1:1000 (Abcam, ab21583), anti-phosphorylated-SMC1, Ser957, 1:1000 (Abcam, ab137871), anti-KAP1, 1:1000 (Abcam, ab190178), anti-phosphorylated-KAP1, Ser824, 1:1000 (Abcam, ab70369), anti-phosphorylated-ATM Ser 198 1:1000 (MERK, Cat. 05-740), anti-p21 (Santa Cruz, Cat. sc-6246), anti-phospho-p53 (Cell Signalling, Cat. 9286S), anti-p53 (Santa Cruz, Cat. sc-98), anti-p53 (Santa Cruz, Cat. sc-55476).
Validation	specific validations were performed for the following antibodies with cell lines deficient for IRE1. anti-HA (Cat: 901514, Biolegend or Cat: 9110, Abcam), anti-HA 1:1000 (Cat: 715500, Invitrogen), anti-IRE1α (Cat: sc-20790, Santa Cruz; and/or Cat: 3294, Cell Signaling Technologies). The rest of antibodies were used as described by manufacturer's instructions and band specificity, when more than one was inferred based on molecular weight.

Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)	IRE1 deficient MEF cells come from David Ron lab. The rest of the cell lines on this study were generated for this study: MEF IRE1-HA, MEF IRE1-MOCK, MEF shRNA control, MEF shRNA c-Abl, MEF CRISPR-Control and MEF CRISPR-c-Abl. HEK293T cells used in this study were obtained from ATCC. TREX cells expressing IRE1 α -3F6HGFP WT were obtained from Dr. Peter Walter at UCSF and were previously described.
Authentication	IRE1 alpha deficient cells or reconstituted were tested by XBP1 splicing and by Western blot.
Mycoplasma contamination	Cell lines used in this study tested negative for mycoplasma. Positive cell lines were treated (Plasmocin™ and/or BIOMYC-1/2) or discarded as a regular basis.
Commonly misidentified lines (See ICLAC register)	No commonly misidentified cell lines were used

Palaeontology

Specimen provenance	<i>Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).</i>
Specimen deposition	<i>Indicate where the specimens have been deposited to permit free access by other researchers.</i>
Dating methods	<i>If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.</i>

☒ Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

Laboratory animals	Mice C57-B6 mice RNase floxed mice for ERN1 were bred with Mx-Cre to generate an inducible liver specific transgenic animals. IRE1α deletion was achieved by injecting intra peritoneal 250 μg of Poly(I:C (Invivogen) three times every two days. 5-6 weeks old mice were intraperitoneally (i.p) injected of poly(I:C). Mice were used for experiments at least 2-3 weeks after the final poly (I:C) injection. Fly studies: Flies were kept at 25°C on standard medium with a 12–12 dark-light cycle. The UAS-Ire1 IR (v39562) line was obtained from the Vienna Drosophila RNAi Center (VDRC). The following lines were obtained from Bloomington Drosophila Stock Center (BDSC): UAS-GFP IR (BL-44412); Ire1 mutant w1118; PBac{WH}Ire1f02170/TM6B (BL-18520); mwh1 mutant (BL-549) and flr3/TM3, Ser stock (BL-2371).
Wild animals	This study did not involve wild animals
Field-collected samples	This study did not involve field collected samples
Ethics oversight	Animal protocols were approved by the Institutional Committee for Animal Care and Handling, University of Chile (Protocol CICUA-CBA-0833).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics	<i>Describe the covariate-relevant population characteristics of the human research participants (e.g. age, gender, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."</i>
Recruitment	<i>Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.</i>
Ethics oversight	<i>Identify the organization(s) that approved the study protocol.</i>

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration	Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.
Study protocol	Note where the full trial protocol can be accessed OR if not available, explain why.
Data collection	Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.
Outcomes	Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.

ChIP-seq

Data deposition

- ☐ Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).
- ☐ Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links <i>May remain private before publication.</i>	For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.
Files in database submission	Provide a list of all files available in the database submission.
Genome browser session (e.g. UCSC)	Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.

Methodology

Replicates	Describe the experimental replicates, specifying number, type and replicate agreement.
Sequencing depth	Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired- or single-end.
Antibodies	Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.
Peak calling parameters	Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.
Data quality	Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.
Software	Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.

Flow Cytometry

Plots

Confirm that:

- ☐ The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- ☐ The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- ☐ All plots are contour plots with outliers or pseudocolor plots.
- ☒ A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation	Membrane permeability was assessed using propidium iodide (PI) staining. Briefly, cells were harvested by trypsinization and incubated 15 min at 37 °C to restore membrane integrity. Cells were collected by centrifugation, resuspended in PBS, stained with 0.6 µg ml ⁻¹ of PI (Sigma-Aldrich 81845), and analyzed using a BD FACS Canto Biosciences flow cytometer (Becton Dickinson).
Instrument	BD FACS Canto Biosciences flow cytometer

Software	BD FACS Canto Biosciences flow cytometer software
Cell population abundance	Describe the abundance of the relevant cell populations within post-sort fractions, providing details on the purity of the samples and how it was determined.
Gating strategy	Describe the gating strategy used for all relevant experiments, specifying the preliminary FSC/SSC gates of the starting cell population, indicating where boundaries between "positive" and "negative" staining cell populations are defined.

☐ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

Magnetic resonance imaging

Experimental design

Design type	Indicate task or resting state; event-related or block design.
Design specifications	Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.
Behavioral performance measures	State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).

Acquisition

Imaging type(s)	Specify: functional, structural, diffusion, perfusion.
Field strength	Specify in Tesla
Sequence & imaging parameters	Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, slice thickness, orientation and TE/TR/flip angle.
Area of acquisition	State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.
Diffusion MRI	☐ Used ☐ Not used

Preprocessing

Preprocessing software	Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.).
Normalization	If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.
Normalization template	Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g. original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.
Noise and artifact removal	Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and physiological signals (heart rate, respiration).
Volume censoring	Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.

Statistical modeling & inference

Model type and settings	Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).
Effect(s) tested	Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.
Specify type of analysis:	☐ Whole brain ☐ ROI-based ☐ Both
Statistic type for inference (See Eklund et al. 2016)	Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.
Correction	Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo).

Models & analysis

- n/a | Involved in the study
- ☐ ☐ Functional and/or effective connectivity
- ☐ ☐ Graph analysis
- ☐ ☐ Multivariate modeling or predictive analysis

Functional and/or effective connectivity

Report the measures of dependence used and the model details (e.g. Pearson correlation, partial correlation, mutual information).

Graph analysis

Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, etc.).

Multivariate modeling and predictive analysis

Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics.